# US 2021/0060071 A1 · Chimeric Antigen Receptor T Regulatory Cells for the Treatment of Atherosclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060071 A1
- Document ID: US20210060071A1
- Status: Published application
- Kind: A1
- Application number: 17/050,527
- Filed: 2019-04-26
- Published: 2021-03-04
- Earliest claimed: 2018-04-27
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Avery D. POSEY; Carl H. JUNE; Robert D. SCHWAB
- Web page: https://patentgrep.com/patent/US20210060071A1

## CPC

- C07K 14/70507: {CD2}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4242: {Transcription factors, e.g. SOX or c-MYC}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/18: against material from animals or humans
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention includes compositions and methods for treating atherosclerosis. In certain embodiments, atherosclerosis is treated using a chimeric antigen receptor (CAR) T cell specific for modified low-density lipoprotein.

## Claims

### Claim 1

A method for treating heart disease and/or atherosclerosis in a subject in need thereof, the method comprising administering to the subject a T cell genetically modified to express a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain specific for modified low-density lipoprotein (LDL), a transmembrane domain, and an intracellular domain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the modified LDL comprises oxidized LDL (OxLDL).

### Claim 3 (depends on 1)

The method of claim 1, wherein the modified LDL comprises an MDA/MDA-ApoB100 epitope present on oxidized LDL (OxLDL).

### Claim 4 (depends on 1)

The method of claim 1, wherein the modified LDL comprises modified ApoB100.

### Claim 5 (depends on 1)

The method of claim 1, wherein the modified LDL is selected from the group consisting of Cu-oxidized LDL, advanced glycation endproducts LDL (AGE-LDL), malondiadehyde-LDL, glycated-LDL, carbamylated LDL, desialylated LDL, apolipoprotein (a), and lipoprotein (a) (Lp-a), oxidized phosphatidylcholine containing oxidized phospholipids, 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC), oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC), 4-hydroxynonenal (HNE), oxidized cholesteryl ester (OxCE), and oxidized cardiolipin (OxCL).

### Claim 6 (depends on 1)

The method of claim 1, wherein the cell is a regulatory T (Treg) cell.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell is a CD4+ T cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cell is a CD4+ T cell that is converted to a regulatory T (Treg) cell.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cell is an autologous T cell.

### Claim 10 (depends on 1)

The method of claim 1, wherein the administering comprises adoptive cell transfer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the antigen binding domain is selected from the group consisting of an antibody, a Fab, or an scFv.

### Claim 12 (depends on 1)

The method of claim 1, wherein the antigen binding domain is an scFv comprising SEQ ID NO: 6.

### Claim 13 (depends on 1)

The method of claim 1, wherein the transmembrane domain is selected from the group consisting of CD28, CD8 alpha, ICOS, and GITR.

### Claim 14 (depends on 1)

The method of claim 1, wherein the transmembrane domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, and SEQ ID NO: 14.

### Claim 15 (depends on 1)

The method of claim 1, wherein the intracellular domain is at least one selected from the group consisting of CD3zeta, CD28, 4-1BB, ICOS, GITR, and CD2.

### Claim 16 (depends on 1)

The method of claim 1, wherein the intracellular domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 23.

### Claim 17 (depends on 1)

The method of claim 1, wherein the intracellular domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 24, and SEQ ID NO: 26.

### Claim 18 (depends on 1)

The method of claim 1, wherein the CAR further comprises a hinge domain.

### Claim 19 (depends on 1)

The method of claim 1, wherein the CAR further comprises a hinge domain comprising SEQ ID NO: 8.

### Claim 20 (depends on 1)

The method of claim 1, wherein the CAR comprises a 2D03 scFv, a CD8a hinge domain, a CD28 transmembrane domain, a CD28 intracellular domain, and a CD3 zeta domain.

### Claim 21 (depends on 1)

The method of claim 1, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 22 (depends on 1)

The method of claim 1, wherein the CAR comprises a 2D03 scFv, a CD8a hinge domain, a CD8a transmembrane domain, a 4-1BB intracellular domain, and a CD3 zeta domain.

### Claim 23 (depends on 1)

The method of claim 1, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 24 (depends on 1)

The method of claim 1, wherein the CAR comprises a 2D03 scFv, a CD8a hinge domain, an ICOS transmembrane domain, an ICOS intracellular domain, and a CD3 zeta domain.

### Claim 25 (depends on 1)

The method of claim 1, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 3.

### Claim 26 (depends on 1)

The method of claim 1, wherein the CAR comprises a 2D03 scFv, a CD8a hinge domain, a GITR transmembrane domain, a GITR intracellular domain, and a CD3 zeta domain.

### Claim 27 (depends on 1)

The method of claim 1, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 4.

### Claim 28 (depends on 1)

The method of claim 1, wherein the CAR comprises a 2D03 scFv, a CD8a hinge domain, a CD8a transmembrane domain, a CD2 intracellular domain, and a CD3 zeta domain.

### Claim 29 (depends on 1)

The method of claim 1, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 5.

### Claim 30 (depends on 1)

The method of claim 1, wherein the treating heart disease and/or atherosclerosis comprises reversing the pro-inflammatory response at sites of plaque formation and/or highly modified LDL deposition.

### Claim 31

An isolated chimeric antigen receptor (CAR) comprising an antigen binding domain specific for modified low-density lipoprotein (LDL), a transmembrane domain, and an intracellular domain.

### Claim 32 (depends on 31)

The isolated CAR of claim 31, wherein the modified LDL comprises oxidized LDL (OxLDL).

### Claim 33 (depends on 31)

The isolated CAR of claim 31, wherein the modified LDL comprises an MDA/MDA-ApoB100 epitope present on oxidized LDL (OXLDL).

### Claim 34 (depends on 31)

The isolated CAR of claim 31, wherein the modified LDL comprises modified ApoB100.

### Claim 35 (depends on 31)

The isolated CAR of claim 31, wherein the modified LDL is selected from the group consisting of Cu-oxidized LDL, advanced glycation end products LDL (AGE-LDL), malondiadehyde-LDL, glycated-LDL, carbamylated LDL, desialylated LDL, apolipoprotein (a), and lipoprotein (a) (Lp-a), oxidized phosphatidylcholine containing oxidized phospholipids, 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC), oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC), 4-hydroxynonenal (HNE), oxidized cholesteryl ester (OxCE), and oxidized cardiolipin (OxCL).

### Claim 36 (depends on 31)

The isolated CAR of claim 31, wherein the OxLDL binding domain is selected from the group consisting of an antibody, a Fab, or an scFv.

### Claim 37 (depends on 31)

The isolated CAR of claim 31, wherein the scFv comprises SEQ ID NO: 6.

### Claim 38 (depends on 31)

The isolated CAR of claim 31, wherein the transmembrane domain is selected from the group consisting of CD28, CD8 alpha, ICOS, and GITR.

### Claim 39 (depends on 31)

The isolated CAR of claim 31, wherein the transmembrane domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, and SEQ ID NO: 14.

### Claim 40 (depends on 31)

The isolated CAR of claim 31, wherein the intracellular domain is at least one selected from the group consisting of CD3zeta, CD28, 4-1BB, ICOS, GITR, and CD2.

### Claim 41 (depends on 31)

The isolated CAR of claim 31, wherein the intracellular domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 23.

### Claim 42 (depends on 31)

The isolated CAR of claim 31, wherein the intracellular domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 24, and SEQ ID NO: 26.

### Claim 43 (depends on 31)

The isolated CAR of claim 31, wherein the CAR further comprises a hinge domain.

### Claim 44 (depends on 31)

The isolated CAR of claim 31, wherein the CAR further comprises a hinge domain comprising SEQ ID NO: 8.

### Claim 45 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises a 2D03 scFv, a CD8a hinge domain, a CD28 transmembrane domain, a CD28 intracellular domain, and a CD3 zeta domain.

### Claim 46 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 47 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises a 2D03 scFv, a CD8a hinge domain, a CD8a transmembrane domain, a 4-1BB intracellular domain, and a CD3 zeta domain.

### Claim 48 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 49 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises a 2D03 scFv, a CD8a hinge domain, an ICOS transmembrane domain, an ICOS intracellular domain, and a CD3 zeta domain.

### Claim 50 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 3.

### Claim 51 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises, a 2D03 scFv, a CD8a hinge domain, a GITR transmembrane domain, a GITR intracellular domain, and a CD3 zeta domain.

### Claim 52 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 4.

### Claim 53 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises a 2D03 scFv, a CD8a hinge domain, a CD8a transmembrane domain, a CD2 intracellular domain, and a CD3 zeta r domain.

### Claim 54 (depends on 31)

The isolated CAR of claim 31, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 5.

### Claim 55 (depends on 31)

An isolated nucleic acid encoding the chimeric antigen receptor (CAR) of claim 31.

### Claim 56 (depends on 55)

A vector comprising the isolated nucleic acid of claim 55.

### Claim 57 (depends on 55)

A modified T cell comprising the isolated nucleic acid of claim 55.

### Claim 58 (depends on 57)

The modified T cell of claim 57, wherein the T cell is an autologous T cell.

### Claim 59 (depends on 57)

The modified T cell of claim 57, wherein the cell is a regulatory T (Treg) cell.

### Claim 60 (depends on 57)

The modified T cell of claim 57, wherein the cell is a CD4+ T cell.

### Claim 61 (depends on 57)

The modified T cell of claim 57, wherein the CD4+ T cell is converted to a regulatory T (Treg) cell.
